Evogene Ltd. (EVGN) Earnings History
Annual and quarterly earnings data from 2012 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 39.8% | -255.4% | -193.7% |
| 2023 | 24.8% | -467.9% | -423.4% |
| 2022 | -105.9% | -1774.0% | -1590.3% |
| 2021 | -222.7% | -3386.0% | -2988.5% |
| 2020 | -217.4% | -2580.3% | -2247.5% |
Download Data
Export EVGN earnings history in CSV or JSON format
Free sign-in required to download data
Evogene Ltd. (EVGN) Earnings Overview
As of March 5, 2026, Evogene Ltd. (EVGN) reported trailing twelve-month net income of -$3M, reflecting +0.4% year-over-year growth. The company earned $-0.32 per diluted share over the past four quarters, with a net profit margin of -1.9%.
Looking at the long-term picture, EVGN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2012.
Evogene Ltd. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including PHGE (-$37M net income), ARMP (-$47M net income, -3.7% margin), MCRB ($5M net income), EVGN has comparable earnings metrics. Compare EVGN vs PHGE →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$16M | +31.0% | -$22M | $-2.89 | -193.7% | -255.4% |
| 2023 | -$24M | +10.4% | -$26M | $-5.23 | -423.4% | -467.9% |
| 2022 | -$27M | +4.2% | -$30M | $-6.46 | -1590.3% | -1774.0% |
| 2021 | -$28M | -18.9% | -$31M | $-0.68 | -2988.5% | -3386.0% |
| 2020 | -$23M | -29.1% | -$27M | $-0.64 | -2247.5% | -2580.3% |
| 2019 | -$18M | +12.7% | -$23M | $-0.70 | -2405.3% | -3019.9% |
| 2018 | -$21M | +0.4% | -$21M | $-0.81 | -1188.2% | -1216.6% |
| 2017 | -$21M | -6.4% | -$22M | $-0.81 | -616.3% | -644.3% |
| 2016 | -$20M | -13.8% | -$21M | $-0.77 | -299.6% | -322.5% |
| 2015 | -$17M | -18.5% | -$18M | $-0.68 | -154.7% | -161.0% |
See EVGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EVGN Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare EVGN vs LLY
See how EVGN stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
Is EVGN growing earnings?
EVGN EPS of $-0.32 reflects slowing growth at +0.4%, below the 5-year CAGR of N/A. TTM net income is $-3M. Expansion rate has moderated.
What are EVGN's profit margins?
Evogene Ltd. net margin is -1.9%, with operating margin at -2.6%. Below-average margins reflect competitive or cost pressures.
How consistent are EVGN's earnings?
EVGN earnings data spans 2012-2024. The current earnings trend is +0.4% YoY. Historical data enables comparison across business cycles.